Zhejiang Orient Gene Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Zhejiang Orient Gene Biotech şirketinin toplam hissedar öz sermayesi CN¥7.1B ve toplam borcu CN¥510.9M olup, bu da borç-öz sermaye oranını 7.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥8.2B ve CN¥1.2B dir.

Anahtar bilgiler

7.2%

Borç/özkaynak oranı

CN¥510.94m

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥3.71b
Eşitlik	CN¥7.05b
Toplam yükümlülükler	CN¥1.18b
Toplam varlıklar	CN¥8.23b

Son finansal sağlık güncellemeleri

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?

Aug 20

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Apr 30

Recent updates

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?

Aug 20

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Apr 30

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 688298 'nin kısa vadeli varlıkları ( CN¥4.6B ) kısa vadeli yükümlülüklerini ( CN¥1.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: 688298 şirketinin kısa vadeli varlıkları ( CN¥4.6B ) uzun vadeli yükümlülüklerini ( CN¥69.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 688298 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 688298 'nin borç/öz sermaye oranı son 5 yılda 8.8% seviyesinden 7.2% seviyesine düştü.

Borç Kapsamı: 688298 'nin işletme nakit akışı negatif olduğundan borçlar iyi karşılanamıyor.

Faiz Kapsamı: 688298 şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

Zhejiang Orient Gene Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Recent updates

Third quarter 2024 earnings released: CN¥0.56 loss per share (vs CN¥0.55 loss in 3Q 2023)

Zhejiang Orient Gene Biotech Co., Ltd to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.43 loss per share (vs CN¥0.41 profit in 2Q 2023)

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?

Zhejiang Orient Gene Biotech Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Revenue and earnings growth

Zhejiang Orient Gene Biotech Co.,Ltd, Annual General Meeting, May 22, 2024

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Full year 2023 earnings released: CN¥1.97 loss per share (vs CN¥10.26 profit in FY 2022)

Now 21% undervalued after recent price drop

Zhejiang Orient Gene Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥1.85 loss per share (vs CN¥10.26 profit in FY 2022)

Zhejiang Orient Gene Biotech Co.,Ltd (SHSE:688298) announces an Equity Buyback for CNY 100 million worth of its shares.

Now 21% undervalued after recent price drop

Third quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥1.54 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥3.35 in 2Q 2022)

Zhejiang Orient Gene Biotech Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Upcoming dividend of CN¥2.00 per share at 4.0% yield

First quarter 2023 earnings released: CN¥0.30 loss per share (vs CN¥12.30 profit in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥17.74 (vs CN¥29.29 in FY 2021)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥1.84 (vs CN¥3.12 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥4.02 (vs CN¥13.14 in 2Q 2021)

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Now 33% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Now 23% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥4.37 (vs CN¥1.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥18.40 (vs CN¥3.96 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥9.89 (vs CN¥0.37 in 1Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥14.07 (vs CN¥0.91 in FY 2019)

New 90-day low: CN¥135

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

New 90-day high: CN¥203

Investor sentiment improved over the past week

New 90-day high: CN¥177

Market bids up stock over the past week

Softlab9 Technologies Inc. Purchases Rapid Antigen COVID Testing Kits from Zhejiang Orient Gene Biotech Co. Ltd

New 90-day low - CN¥123

New 90-day high - CN¥260

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin